## IX BIOPHARMA LTD.

(Company Registration Number 200405621W) (Incorporated in the Republic of Singapore)

## PROPOSED ISSUANCE OF CONVERTIBLE BONDS OF AN AGGREGATE PRINCIPAL AMOUNT OF \$\$2,000,000

- RECEIPT OF LISTING AND QUOTATION NOTICE FROM THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED

The Board of Directors (the "Board") of iX Biopharma Ltd (the "Company", and collectively with its subsidiaries, the "Group") refers to its announcement dated 3 July 2023 (the "Previous Announcement") in respect of issuance of S\$2,000,000 in principal amount of interest-bearing convertible bonds, which are convertible into new ordinary shares in the capital of the Company (the "Proposed CB Issuance").

Unless otherwise stated, all capitalised terms used herein shall bear the same meanings as ascribed to them in the Previous Announcement.

Further to the Previous Announcement, the Board is pleased to announce that the Company has on 17 July 2023, received the listing and quotation notice ("**LQN**") from the Singapore Exchange Securities Trading Limited ("**SGX-ST**") for the listing of and quotation of up to 24,420,024 Conversion Shares on Catalist, subject to compliance with the listing requirements of the SGX-ST.

The LQN is not to be taken as an indication of the merits of the Proposed CB Issuance, the Conversion Shares, the Company and / or its subsidiaries.

The Company will continue to keep Shareholders updated and make the necessary announcement(s) in relation to the Proposed CB Issuance as and when required.

By Order of the Board

Gwendolin Lee Soo Fern/Lai Kuan Loong, Victor Company Secretaries

17 July 2023

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.